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Inhibitor Response to TKIs in Non-small Cell Lung Cancer:
An Analytical Database
Samuel Murray, PhD,* Issa J. Dahabreh,† Helena Linardou, MD, PhD,‡
Menelaos Manoloukos, MSc,* Dimitrios Bafaloukos, MD,‡ and Paris Kosmidis, MD§
Background: After the discovery of somatic mutations in the
tyrosine kinase domain (exons 18–24) of the epidermal growth
factor receptor (EGFR) correlating with responses of non-small cell
lung cancer (NSCLC) to the tyrosine kinase inhibitors (TKIs)
gefitinib and erlotinib, there has been increasing interest in utilizing
this molecular marker for treatment selection. We aimed to analyt-
ically catalogue the mutational spectrum of somatic mutations in
EGFR and format a database allowing correlation of specific muta-
tions with clinico-pathologic factors and response to TKIs.
Methods: A computerized search of MEDLINE (January 1, 2004 to
June 30, 2007) was performed to identify articles reporting on
NSCLC patients harboring somatic mutations in EGFR. Demo-
graphic, clinico-pathologic, mutational, and response data were
extracted and tabulated.
Results: A total of 202 eligible articles were identified. We report
data on 12,244 patients with 3381 somatic EGFR mutations. The
majority of mutations have been reported on only one occasion (158
of 254, 62.2%), and only nine mutations occur at a rate of 1%.
L858R and delE746-A750 account for 32.84% and 24.28% of all
mutations, respectively; with 50% of mutations being exon 19
deletions or “deletional-insertions.” There is a clear association
between the presence of mutations and response to TKI.
Conclusions: We have generated a free access, nonprofit online
analytical database of somatic EGFR mutations in NSCLC. Cumu-
lative information will be made available through a routine update of
both database tables and associated graphical representations. Direct
updates and submissions through the online site (www.somaticmutations-
EGFR.org) are encouraged, as are comments and suggestions.
KeyWords: Gefitinib, Erlotinib, Non-small cell lung cancer, Smok-
ing, Adenocarcinoma.
(J Thorac Oncol. 2008;3: 832–839)
The clinical course of non-small cell lung cancer (NSCLC)has seen potentially important changes over the last few
years after the introduction of tyrosine kinase inhibitors
(TKIs) as a treatment modality.1–6 With this introduction,
clinical perceptions on both treatment and outcome have also
seen some significant changes. Oral bioavailability, and daily
administrative schedules are hallmarks of these new mole-
cules that target the epidermal growth factor receptor
(EGFR).7,8 Newfound enthusiasm in the treatment of meta-
static disease has however diminished after the rapid com-
pletion of a number of rather disappointing phase III stud-
ies,9–12 resulting in the clinical approval for only one of two
current 4-anilinoquinazolines, single agent erlotinib for the
second-line treatment of NSCLC in the United States and
Europe.4,6
In early 2004, somatic mutations in the tyrosine kinase
(TK) domain of EGFR were identified, correlating with
responses to these agents.1,13,14 Since then numerous groups
have compiled data on the mutational spectrum of EGFR with
respect to incidence, clinico-pathologic correlates, prognostic
and predictive significance, response to TKIs and surviv-
al.15–22 Several questions have been raised regarding the
significance of their origin, Ras mutations, EGFR gene copy
number, specific clinico-pathologic correlates (smoking sta-
tus, gender, etc.), and more recently the role of mutations as
predictive markers.
Since the first reports of EGFR mutations occurring in
NSCLC, there has been an exponentially growing number of
publications presenting data on the incidence of EGFR mu-
tations in patients treated with TKIs correlating their presence
with responses, and documenting the existence of such mu-
tations in TKI-naive patients. In this systematic review, we
aim to retrieve all published information on EGFR mutational
status, categorize, and tabulate it according to the relevant
clinico-pathologic parameters and finally, initiate the devel-
opment of an independent patient level EGFR mutation
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database supporting the EGFR mutational spectrum while
tabulating treatment responses. The database is designed to
be flexible for the inclusion of any additional fields that are
deemed appropriate in relation to somatic mutations of
EGFR. The database provides a graphical overview of the
complexity of the somatic mutational spectrum, while allow-
ing readers to gain a picture of the efficacy of TKIs in patients
with specific somatic mutations.
MATERIALS AND METHODS
Identification of Published Material
We performed a systematic computerized search of the
MEDLINE (PubMed) database (last search: July 1, 2007) to
identify all published articles from January 1, 2004 to June
30, 2007 dealing with the identification of somatic mutations
in EGFR pertaining to NSCLC, using the algorithm: (epider-
mal growth factor receptor OR EGFR OR gefitinib or non-
small cell lung cancer OR NSCLC OR erltinib OR iressa
OR tarceva) AND (mutation OR gefitinib OR iressa). We
hand searched journals known to publish data relevant to our
search, the reference lists of all articles we recovered and
those of relevant review articles were also cross-referenced.
We contacted experts in the field of NSCLC to broaden our
yield of potentially eligible articles. Because of glitches in the
search engine and unintentional handling errors, there is the
distinct possibility that one or more articles escaped our
search. Through a process of planned author contact and
updates it is expected that the database will become more
complete.
Eligibility Criteria
We considered only peer-reviewed published articles
with data pertaining to the somatic mutation analysis of the
TK domain of EGFR (with a minimum requirement of at least
investigation of one of exons 18 through 21), or any specific
mutation (i.e., L858R) in NSCLC samples. Abstracts and
meeting proceedings were excluded and no language restric-
tion was imposed. Single patient data (including case reports)
were included where at all possible. There was no exclusion
based on the number of patients screened or completeness of
field term identifiers per study. No restriction was placed on
the method of mutational analysis (e.g., specific mutations
such as L858R by restriction fragment length polymorphism
through to whole gene sequencing, bidirectional sequencing,
TaqMan probes identifying specific mutations, were eligible);
nor the source of biological material (e.g., paraffin embedded
biopsy, fresh frozen biopsy, cytologic specimens); nor the
nature of the molecular analysis (e.g., RNA or DNA).
When multiple reports on the same population were
available, we retained only the report with the largest number
of events or largest patient population (where appropriate) to
avoid duplication of information. Because of the cumulative
nature of the data reporting and size restrictions it was
inappropriate to perform any statistical analysis at this time
point; therefore, all tabulated data is only descriptive in
nature. Furthermore, because of the possibility of repeated
data reporting or overlapping data, all studies with fewer than
five screened patients have been removed from the final
descriptive tabulated data, unless otherwise stated. The mu-
tational spectrum has been generated from cumulating all
possible data sets, as has the response per mutation data
(inclusive of case reports, wherever not obviously of an
overlapping nature).
Data Extraction
Information recorded about each recovered reference is
listed in Table 1. All publications were reviewed indepen-
dently by two of the authors (SM and IJD), discrepancies
were resolved by these two authors. Manually extracted
information included EGFR mutational rate, mutation type
(spectrum), correlations with clinico-pathologic and demo-
graphic data (smoking status, gender, histologic type), and
also for data linking specific somatic mutations to treatment
outcome (complete response [CR], partial response [PR],
stable disease, progressive disease [PD], non-evaluable) with
the TKIs gefitinib and erlotinib when administered as single
agent, i.e., monotherapy TKI. No stratification has been made
according to TKI with respect to response data. Data sets
including patient information from populations treated with a
TKI in combination with another agent (either chemotherapy
or another biological modifier) were not included in the
response outcome calculations.
Data sets, particularly those including information
overlapping partially with previous publications that allowed
extraction of relevant information (see field terms in Table 1)
were reported on more than one occasion to achieve the
highest completeness of data for inclusion in the database.
Subanalyses have taken into account repetitive data presen-
tation after cross-analysis and comparisons based on the list
of authors, host-institution, relevant clinical studies, and
sources(s) of biological material(s). Updates and author con-
firmation will be conducted routinely to improve data accu-
racy. Because of the complexity of some published data sets,
more than one data entry may have been included in the
database to reflect completeness of data extraction.
Terminology and Fields
Field terms corresponding to data extracted from each
article regarding mutational spectrum and clinico-pathologic
correlates are explained in Table 1. To simplify the current
complexity with respect to somatic mutations of EGFR, we
have reported mutations in a simplified manner (Table 2).
Notation
Mutations were not labeled directly according to the
Human Genome Variation Society (www.hgvs.org/mut-’
nomen) guidelines. Mutations were labeled according to the
amino acid (AA) sequence, (reference mRNA sequence gi:
29725608; GenBank Accession NM_005228.2) with the
translation initiation site methionine (ATG) corresponding to
nucleotide 167. Various authors have used the common
Human Genome Variation Society nomenclature; however,
we believe that the majority of clinicians, and therefore the
majority of diagnostic laboratories, will ultimately report the
mutational spectrum with respect to alterations in the AA
sequence and not necessarily in the nucleotide sequence.
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Database Format
Clinico-pathologic and response information and the
mutational spectrum were tabulated. These make up the back-
bone of the database (www.somaticmutations-EGFR.org) and
are maintained in an Excel format as simple spreadsheets. All
figures and tables have been compiled by direct data extrac-
tion utilizing Microsoft Power-Point and Excel. All data sets
and subanalyses will be available as PDF files through the
Web site (updated q6m), and as supplemental data through
the journal.
Other Mutations
All other mutations will be incorporated in a separate
list of mutations, namely mutations occurring outside of
exons 18–21, and also all silent mutations.
Limitations
There are numerous limitations associated with such a
database. Many of these are discussed in Supplementary
Notes I.
TABLE 2. Mutation Terminology
Deletions Consecutive nucleotide loss
Insertions Consecutive nucleotide insertion and/or
duplication
Duplications Duplications, as in insertions
Deletional-insertions There are a variety of possible scenarios for this
event including (1) colocalization of an
insertion and a deletion; (2) two nonadjacent
(1nt) mutations being either dual insertions or
deletions; (3) more complex rearrangements.
All of these have been simplified to align
directly with the coding region and are reported
simply as deletions (across the region) plus the
associated amino acid insertion
Mutation Only those that change the reference amino acid
sequence (gi: 29725608), i.e., missense and
frameshift mutations that alter the amino acid
sequence have been included, however, silent
somatic mutations have not been included in
the analysis and are separately reported in the
database
TABLE 1. Field Terms Extracted
Reference Data sets represented by a given reference, references may appear on more than one occasion depending on the extent of data
extraction. i.e., treated and nontreated populations from the same article are presented separately if possible
Mutation type Reported as per Table 2. All refer to the amino acid sequence number assigned according to reference sequence gi:
29725608. Amino acid alterations are reported as single letter abbreviations
Confirmed somatic Confirmed to be somatic by analysis of normal cells; yes or no (in most instances not all samples have been proven somatic)
2 mutations Patients with 2 reported somatic mutation are noted, these include patients with T790M, BUT do not include patients with
silent polymorphisms or germ line single nucleotide polymorphisms (SNPs). Patients with T790M mutations have typically
developed the mutation following TKI-based therapy; therefore, the majority of these patients have already been included
in the tables (both mutation and response). Readers are advised to investigate these cases with caution. All other cases of
dual (or multiple) mutations occurring in one individual have been recorded in both the mutation and response tables as
independent events according to each individual mutation. Therefore, there are additional patient numbers associated
throughout the data set and the associated tables. Considering that they represent approximately 1.7% of the total
population readers are advised to interpret the presented tables and data sets bearing this in mind
Gender   male;   female
Ethnicity Based on ethnicity of the biological specimens used in the study. More than one ethnicity may occur per reference
Pathology (histological
type)
Adenocarcinoma  adenocarcinomas combined with any histology with BAC component (bronchioalviolar component, e.g.,
BACs, AWFB, BWFI), adenosquamous are included with other; Other, all other histologies
Smoking status Smoker  current, previous with no limit on pack year; nonsmoker  assumed never smokers
TKI Tyrosine kinase inhibitor (TKI); E  erlotinib (Tarceva); G  gefitinib (Iressa). As yet no data has been assigned to
combination versus single agent therapy, nor treatment period, or disease stage; C  chemotherapy
Response criteria Reported as RECIST (R), WHO, SWOG
Author confirmation
and date
Date at which corresponding author confirmed the data set
Sample source PET  paraffin embedded tissue; FF  fresh frozen tissue; Other  as indicated
Analyte DNA  mutational analysis conducted on extracted DNA; RNA  mutational analysis conducted on tissue extracted RNA
Exons examined Exons screened per study (individual mutation through to entire gene)
Technique Seq  bidirectional sequencing; RFLP  restriction fragment length polymorphism; TaqMan  TaqMan probes (typically 13
different mutations, unless otherwise stated); surveyor  combined Taqman-like format with enhancement of mutant allele;
SSCP  single strand conformational polymorphism; MEP  mutant-enriched PCR
ˆ Not reported, or not directly extractable from the data source
Treatment response CR  complete response; PR  partial response; SD  stabilization of disease; PD  progressive disease; NE 
nonevaluable
Treatment status Status at the time of TKI initiation: P  previously treated with chemotherapy, determined to be ineligible to receive
standard chemotherapy; N  chemotherapy naïve
No. of patients—WT Number of samples with wild type EGFR sequence (WT)
No. of patients—mutant Number of samples with a somatic mutation in EGFR (Mut)
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Updates
The database will be updated q6 months after a con-
tinuing literature search conducted as mentioned. Data will be
cross-checked, authors contacted through the database for
confirmation, and updates made of all figures and tables
posted on the Web site.
Data Submissions
An Excel-based worksheet containing all of the fields
included in this database is available from the Web site
(www.somaticmutations.org) for authors willing to directly
submit their information. All information will be manually
reviewed and all submitting authors will be contacted for
completeness before inclusion within the database.
RESULTS
Data Extraction
In this review, we have compiled data according to the
trial flow (Figure 1). During the search period, a total of
12,244 patients (extracted from 202 eligible articles from an
original pool of 2385 articles of potential interest) have been
screened for somatic mutations in EGFR. Over this time, the
number of both publications and reported somatic mutations
in EGFR has increased dramatically. A complete set of
extracted data is presented within the primary database of the
site. Data is available from a total of 2548 patients treated
with a TKI for which somatic EGFR mutational data is
available (131 eligible articles with treatment:response data).
Considering that ethnicity is correlated with the incidence of
EGFR mutations all tabulated data has been stratified for
ethnicity, Asians versus Whites.
Mutational Spectrum and Incidence
We have catalogued the somatic mutational spectrum
(principally of exons 18–21) of EGFR identifying a total of
3381 independently reported somatic mutations from 12,244
screened individuals. In some cases, because neither the
specific mutation identification techniques nor for the lack of
data reporting a number of these mutations have been local-
ized within any specific exon, therefore, the total number of
mutations is 3303 (Figure 2A). It must also be noted that
because of the possibility of more than one somatic mutation
occurring in any given sample, the actual number of individ-
uals with somatic mutations of EGFR is 3188. The overall
mutational spectrum and the reported incidence for each
mutation are also graphically displayed per exon within the
database. The “deletional” and “insertional” mutations that
occur in exons 19 and 20 have been independently repre-
sented, as have single AA substitutions per exon.
The relative frequency of the different mutational types
per exon is indicated in Table 3. From a total of 186 AAs that
constitute exons 18–21, 109 (58.6%) are implicated in at least
one form of somatic mutation. Figure 3 indicates the relative
frequency of mutation reporting in relation to the number of
occasions a specific mutation has been reported. The majority of
the mutational spectrum occurs at a very low rate, with 158
of 254 (62.2%) different mutational types being reported on one
occasion. Furthermore, by adding mutations that have only been
reported in one article, this increases to 181 (71.3%). Only a
FIGURE 1. Trial flow of database generation and data ex-
traction.
FIGURE 2. Distribution of somatic EGFR mutations. A, per
exon and B, according to type (entire population).
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small proportion of all mutations have actually been reported at
a frequency of 5 occasions.
The two most common mutations, L858R located in
exon 21 representing 32.84% of all mutations and delE746-
A750 representing 24.28%, account for the majority of all
reported mutations. Deletions and “deletional-insertions” in
exon 19 alone account for 47.35% of all reported mutations,
with deletions and deletional-insertions combined from all
exons constituting more than half of all mutations (Figure
2B). From the large number of different mutations occurring
within these four exons, there are only a few that occur at a
frequency of close to or 1% (Table 4).
Efficacy
A cumulative representation of the overall response per
exon and response per mutational type are shown (Figure 4).
Mutations in exon 19 have an 86.21% overall response rate
compared with only 33.33% for exon 20. Further subanalysis
of these responses indicates that, in the absence of a T790M
somatic mutation, the chance of an individual responding to
TKI monotherapy in the presence of a mutation in exon 20 is
approximately 68%, comparable to that of exon 18. Except
for the T790M, few other exon 20 mutations actually display
de novo resistance to TKI treatment. In fact, out of 115
different mutations for which response data were available,
there are only 28 (24.35%) that are associated with lack of
response, and 13 different mutations that have only demon-
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FIGURE 3. Frequency of reported incidence of somatic mu-
tations in EGFR. Incidence of somatic mutations that have
been reported on 1, 2, 3, 4, and 5 separate occasions.
Also the number (incidence) of mutations that have a cumu-
lative frequency of 1% of the total number of mutations
reported (n  3305).
FIGURE 4. Response rates for somatic mutations per exon,
total population, and per mutational type (cumulative data
of treated patients for which response data exists). Re-
sponses are characterized as CR  PR, stable disease (disease
stabilization), PD, nonevaluable. Total represents the per-
centage of each response group per stratification out of
100%. Point mutations represent missense mutations and
frameshift mutations, Dels-Ins are a combination of dele-
tions, insertions, and deletional-insertions (according to
Table 2). All  all mutations.
TABLE 3. Frequency and Types of Independent Somatic Mutations Identified
Exon
Total
(186 AA’s)18 (41 AA’s) 19 (32 AA’s) 20 (61 AA’s) 21 (52 AA’s)
Amino acids affected 20 (48.8%) 25 (78.1%) 31 (50.8%) 33 (63.5%) 109 (58.6%)
Insertions and/or duplications 0 4 27 0 31
Deletions and/or
deletional-insertions
0 70 8 0 78
Mutations 38 24 39 44 145
Total 38 98 74 44 254
AA, amino acid. Two independent exon 22 somatic mutations have been identified, E884K and V897I (one occasion each).
TABLE 4. Incidence of the Most Common Specific Somatic
Mutations of EGFR in NSCLC. Mutations and Incidence
(Approximate %) are Reported as Determined Utilizing
Independent Specific Mutation Data (n  2776)
Mutation Incidence (%)
E709 0.86
G719 2.99
delE746-A750 28.89
delE746-T751insA 0.86
delE746-S752insV 1.30
delL747-A750insP 1.73
delL747-T751 1.62
delL747-S752 0.79
delL747-P753insS 2.49
S768 0.68
T790M 2.23
L858 39.37
L861 1.33
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strated PD as a response (8 of which are located in exon 20).
In total, from 776 cases where response can be correlated to
a specific somatic mutation, there are 102 (13.14%) cases of
PD. Data presented in Figure 4 needs to be interpreted with
caution because the two main mutations account for approx-
imately 90% of all mutations, and furthermore, there are
cases of individuals with dual mutations. In these cases, the
response to one of the two mutations may be masked by that
of the other, leading to some inconsistencies in the response
data presented herein.
DISCUSSION
Many aspects of the origin, incidence, response to TKI
in the presence of such mutations, and associated molecular
mechanisms of clinical response have been addressed by
numerous reviews.23–25 In this analytical database, we ad-
dress issues pertaining to the incidence and clinical applica-
tion of somatic EGFR mutations in NSCLC by providing a
global picture, for use by both diagnostic laboratories and
clinicians, in predicting the response to a TKI in the presence
of distinct somatic EGFR mutations. The database also serves
as a source of clinico-pathologic correlations and for the
identification of differences according to ethnicity. It is be-
lieved that this database will allow for the generation of a
more detailed appraisal of the somatic mutational spectrum
of EGFR.
Gu et al.26 have presented an updated version of a
similar somatic EGFR mutation database; however, they have
limited its scope to mutation carriers and have not collected
information on wild-type cases. The mutational spectrum
itself is also more readily presented herein, combined with
information linking the mutational spectrum of TKI-treated
individuals to response. Although cumulative data regarding
response per specific mutation is somewhat misleading, it is
hoped that this data will assist in treatment-based decisions
that are more restricted when one relies on single reports.
Considering that virtually 90% of all mutations actually
occur as either delEx19 and/or L858R, these two mutational
“hot spots” have been extensively studied. Therefore, one can
expect a degree of reporting bias concerning these two
mutational types compared with all others in the mutational
spectrum especially when we consider that many groups have
chosen to selectively focus on the incidence of these two
mutations.27–29 A subset analysis according to the complete-
ness of the mutational screen used per study will assist in
more clearly identifying the actual mutational frequency of
each given mutation. Nevertheless, because the majority of
mutations are localized to two distinct regions of the gene, it
is rather more likely that subsequent analyses will concentrate
on these two regions, at the expense of all other mutations.
Therefore, there is a clear need for an analytical database to
include all data, especially when it is representative of rare
mutations.
Several clinico-pathologic parameters have been shown
to correlate with the presence of somatic mutations of the TK
domain of EGFR as indicated in early studies, theses includ-
ing gender, histology, ethnicity, and smoking history. These
have been reproducibly correlated with the presence of so-
matic missense mutations in EGFR and also with better
response(s) to TKIs.2,3,13,14 As we do not have independent
patient data, we are unable to effectively correlate any of the
common clinico-pathologic factors with response. Rather, we
have the opportunity to correlate these factors with muta-
tional status.
In reviewing the existing data on the correlation of
clinico-pathologic parameters with mutational spectrum in
patients treated or naive to TKIs, it has become apparent that
although there is sufficient information to perform retrospec-
tive (pooled) analyses, one of the major limitations includes
the lack of adequate specimens, especially from some of the
largest studies yet conducted in NSCLC. Recently, each of
the five largest studies of TKIs have reported molecular
analyses; TRIBUTE (carboplatin  paclitaxel with erlotinib
or placebo, 1079 patients) reported on only 21% of enrolled
patients11,21; INTACT-1 (cisplatin  gemcitabine with ge-
fitinib or placebo, 1093 patients),9,30 INTACT-2 (carboplatin 
paclitaxel with gefitinib or placebo, 1037 patients)10 and
BR.21 (erlotinib or placebo, 731 patients)4,31 each reported on
only 28% of enrolled patients; and ISEL (gefitinib versus
placebo, 1692 patients32) reported on less than 23% of en-
rolled patients for any biomarker tested.33 Correlative studies
from the TALENT trial have yet to be published.12 Obvi-
ously, the availability of biological material from all of these
studies would have greatly assisted in further unlocking the
significance of EGFR and other potential molecular markers.
Here, we tabulate the currently existing data concerning the
four main clinico-pathologic factors (gender, ethnicity, smok-
ing history, and histology). Based on our database, we believe
that the tabulated data weighs in favor of supporting a
correlation between mutation and clinico-pathologic param-
eters (a more comprehensive analysis is forthcoming).
In the reported series, for which all relevant data was
extractable, the response rate for mutation carriers is signif-
icantly superior to that of wild type individuals, regardless of
ethnicity (data not shown). Because of the relative low
number of patients per study and also the overall limited
experience with TKIs in populations for which mutational
data is available, the most appropriate way to quantitatively
determine the benefit obtained for TKI-treated mutation car-
riers versus wild type patients will be through a meta-analysis
(preferably with independent patient data). There seem to be
no large studies that could allow the formulation of a solid
opinion on the clinical benefit offered by TKIs in mutation
carriers, principally because of the low level of sample
recruitment in large phase III studies. Nevertheless, the da-
tabase leads us to speculate that the generally held view that
TKIs do offer significant improvements in response to pa-
tients with EGFR mutant tumors compared to those with
wild-type tumors.
Only two studies have addressed the association be-
tween EGFR mutation and survival, one in an independent
patient data pooled analysis of 506 patients from mainland
China (only 57 patients were eligible for survival), and the
other in a pooled analysis of five prospective studies from
Japan that reported on patients treated with gefitinib after
having been selected on the basis of carrying EGFR muta-
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tions (101 patients).34,35 Although the response rate of exon
19 versus exon 21 (delExon19 versus L858R) may be differ-
ent as ascertained from our database, they reported a response
rate (CR/PR) for exon 19 deletion and L858R of 80.3% and
81.8%, respectively. It is unlikely that the data obtained from
our database will change significantly over time, therefore,
the pooled data from these 101 patients needs to be inter-
preted in light of the depth of the current data set.
Through initiation of this database we have (1) gener-
ated a user-friendly interface providing combined/cumulative
data on mutational spectrum and incidence per AA of somatic
mutations in EGFR; (2) tabulated data per study with respect
to mutational rate for all informative clinico-pathologic fields
(gender, histology, smoking status), and other relevant infor-
mation including sample source, method(s) of analysis, spe-
cific exons analyzed, confirmation of somatic nature, etc.; and
(3) combined cumulative data on mutational spectrum and
response characteristics for TKI-treated patients per mutation
and presented them in a user-friendly format facilitating
access to mutation-specific response rate(s), for all such
possible data. The EGFR somatic mutation database and
associated subanalyses are available through a Web site
(www.somaticmutations-EGFR.org) that will be updated q6
months. The generation of this database provides a first step
towards a free access independent patient database from
which significant improvements in NSCLC outcomes
could arise. Through the development of additional col-
laborative efforts (e.g., www.TKI-CAN.org), we hope to
see a broadening in our understanding of the origin of
somatic mutations in EGFR.
We believe that the simplified representation of the data
sets will be extremely useful not only for researchers in the
field but more specifically for clinical teams who are utilizing
the somatic mutational status of EGFR in treatment-based
decisions for patients with NSCLC. We would like to invite
all authors of published studies to confirm their datasets and
welcome updates or new submissions to be made directly
through our online site plus your comments and suggestions.
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